New Opioid Compound Shows Promise for Pain Relief with Reduced Risks

Researchers develop RO76, a fentanyl derivative that effectively suppresses pain in mice while minimizing fatal side effects and withdrawal symptoms.

RO76 targets an unconventional spot on the opioid receptor, reducing respiratory depression compared to morphine.
The compound successfully crosses the blood-brain barrier, essential for effective pain relief.
In animal tests, RO76 demonstrated similar pain-suppressing effects to morphine but with fewer withdrawal symptoms.
The new derivative shows potential for development as an oral medication for humans.
Research was conducted by teams from Washington University, University of Florida, and Stanford University.